Latest News and Press Releases

Vera Therapeutics' management team will present at the TD Cowen Immunology & Inflammation Summit (Nov. 12-13, 2025).

Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week...

Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September 30, 2025

Vera Therapeutics to host an investor call and Webcast to provide an ORIGIN 3 update on November 6, 2025 at 4:30 pm ET.

ROCKVILLE, Md., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation, joined by more than 50 advocates living with rare kidney diseases, are...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency...

EXTON, PA, May 08, 2025 (GLOBE NEWSWIRE) -- With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA...

EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the...